Literature DB >> 24046192

Molecular genetics of familial hematuric diseases.

Constantinos Deltas1, Alkis Pierides, Konstantinos Voskarides.   

Abstract

The familial hematuric diseases are a genetically heterogeneous group of monogenic conditions, caused by mutations in one of several genes. The major genes involved are the following: (i) the collagen IV genes COL4A3/A4/A5 that are expressed in the glomerular basement membranes (GBM) and are responsible for the most frequent forms of microscopic hematuria, namely Alport syndrome (X-linked or autosomal recessive) and thin basement membrane nephropathy (TBMN). (ii) The FN1 gene, expressed in the glomerulus and responsible for a rare form of glomerulopathy with fibronectin deposits (GFND). (iii) CFHR5 gene, a recently recognized regulator of the complement alternative pathway and mutated in a recently revisited form of inherited C3 glomerulonephritis (C3GN), characterized by isolated C3 deposits in the absence of immune complexes. A hallmark feature of all conditions is the age-dependent penetrance and a broad phenotypic heterogeneity in the sense that subsets of patients progress to added proteinuria or proteinuria and chronic renal failure that may or may not lead to end-stage kidney disease (ESKD) anywhere between the second and seventh decade of life. In addition to other excellent laboratory tools that assist the clinician in reaching the correct diagnosis, the molecular analysis emerges as the gold standard in establishing the diagnosis in many cases of doubt due to equivocal findings that complicate the differential diagnosis. Recent work led to the description of candidate genetic modifiers which confer a variable risk for progressing to chronic renal failure when co-inherited on the background of a primary glomerulopathy. Finally, more families are still waiting to be studied and more genes to be mapped and cloned that are responsible for other forms of heritable hematuric diseases. The study of such genes and their protein products will likely shed more light on the structure and function of the glomerular filtration barrier and other important glomerular components.

Entities:  

Keywords:  Alport-TBMN-CFHR5/C3GN-GFND; COL4-CFHR5-FN1; familial microscopic hematuria; genetic and phenotypic heterogeneity; genetic modifiers

Mesh:

Substances:

Year:  2013        PMID: 24046192     DOI: 10.1093/ndt/gft253

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  26 in total

Review 1.  Exploring the genetic basis of early-onset chronic kidney disease.

Authors:  Asaf Vivante; Friedhelm Hildebrandt
Journal:  Nat Rev Nephrol       Date:  2016-01-11       Impact factor: 28.314

2.  Genetic background influences cardiac phenotype in murine chronic kidney disease.

Authors:  Samantha Neuburg; Corey Dussold; Claire Gerber; Xueyan Wang; Connor Francis; Lixin Qi; Valentin David; Myles Wolf; Aline Martin
Journal:  Nephrol Dial Transplant       Date:  2018-07-01       Impact factor: 5.992

Review 3.  Pathogenesis of glomerular haematuria.

Authors:  Claudia Yuste; Eduardo Gutierrez; Angel Manuel Sevillano; Alfonso Rubio-Navarro; Juan Manuel Amaro-Villalobos; Alberto Ortiz; Jesus Egido; Manuel Praga; Juan Antonio Moreno
Journal:  World J Nephrol       Date:  2015-05-06

Review 4.  The Genetics of IgA Nephropathy: An Overview from Western Countries.

Authors:  John Feehally; Jonathan Barratt
Journal:  Kidney Dis (Basel)       Date:  2015-04-23

Review 5.  Haematuria as a risk factor for chronic kidney disease progression in glomerular diseases: A review.

Authors:  Juan Antonio Moreno; Claudia Yuste; Eduardo Gutiérrez; Ángel M Sevillano; Alfonso Rubio-Navarro; Juan Manuel Amaro-Villalobos; Manuel Praga; Jesús Egido
Journal:  Pediatr Nephrol       Date:  2015-05-17       Impact factor: 3.714

6.  Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways.

Authors:  Ivan G Gomez; Deidre A MacKenna; Bryce G Johnson; Vivek Kaimal; Allie M Roach; Shuyu Ren; Naoki Nakagawa; Cuiyan Xin; Rick Newitt; Shweta Pandya; Tai-He Xia; Xueqing Liu; Dorin-Bogdan Borza; Monica Grafals; Stuart J Shankland; Jonathan Himmelfarb; Didier Portilla; Shiguang Liu; B Nelson Chau; Jeremy S Duffield
Journal:  J Clin Invest       Date:  2014-11-21       Impact factor: 14.808

7.  Variants in genes coding for collagen type IV α-chains are frequent causes of persistent, isolated hematuria during childhood.

Authors:  Joseph L Alge; Nasim Bekheirnia; Alexandra R Willcockson; Xiang Qin; Steven E Scherer; Michael C Braun; Mir Reza Bekheirnia
Journal:  Pediatr Nephrol       Date:  2022-06-27       Impact factor: 3.651

8.  Pentraxin-2 suppresses c-Jun/AP-1 signaling to inhibit progressive fibrotic disease.

Authors:  Naoki Nakagawa; Luke Barron; Ivan G Gomez; Bryce G Johnson; Allie M Roach; Sei Kameoka; Richard M Jack; Mark L Lupher; Sina A Gharib; Jeremy S Duffield
Journal:  JCI Insight       Date:  2016-12-08

9.  Novel deletion mutation in a Chinese family with X-linked alport syndrome.

Authors:  Yongzhen Li; Qingnan He; Yanran Wang; Ying Wang; Xiqiang Dang; Xiaochuan Wu; Xiaoyan Li; Lanjun Shuai; Zhuwen Yi
Journal:  Int J Clin Exp Pathol       Date:  2018-09-01

Review 10.  Expert consensus guidelines for the genetic diagnosis of Alport syndrome.

Authors:  Judy Savige; Francesca Ariani; Francesca Mari; Mirella Bruttini; Alessandra Renieri; Oliver Gross; Constantinos Deltas; Frances Flinter; Jie Ding; Daniel P Gale; Mato Nagel; Michael Yau; Lev Shagam; Roser Torra; Elisabet Ars; Julia Hoefele; Guido Garosi; Helen Storey
Journal:  Pediatr Nephrol       Date:  2018-07-09       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.